Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33,170 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo, Clear all

Conditions: Obesity, Overweight, Weight Maintenance
Interventions: VRB-101, Placebo; Drug
Lead sponsor: Verdiva Bio Dev Limited; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 20
States / cities: Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more

Conditions: Schizotypal Personality Disorder, SPD
Interventions: Cognitive Remediation Therapy, Guanfacine, Placebo; Behavioral · Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Pancreatitis, Mesenchymal Stem Cells
Interventions: Bone marrow-derived mesenchymal stem cells, Placebo; Biological · Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: Sibutramine hydrochloride, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 55 Years and older
Enrollment: 10,777 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Healthy Aging
Interventions: Roll Tilt Training, Translation Training, Both Tilt and Translation Training, Placebo Control; Behavioral
Lead sponsor: Ohio State University; Other
Eligibility: 65 Years to 89 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Overweight and Obesity
Interventions: Juice Plus; Dietary Supplement
Lead sponsor: Griffin Hospital; Other
Eligibility: 18 Years to 75 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Derby, Connecticut

Conditions: Schizophrenia
Interventions: AMG 747, Placebo; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 18
States / cities: Anaheim, California • Cerritos, California • Culver City, California + 15 more

Conditions: Schizophrenia
Interventions: vabicaserin, risperidone, placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more

Conditions: Healthy, Premenstrual Dysphoric Disorder, Premenstrual Syndrome
Interventions: Mixhers HERTIME, Placebo; Dietary Supplement
Lead sponsor: Midwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Glendale, Arizona

Conditions: Graft vs. Host Disease
Interventions: Obinutuzumab, Placebo; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 5
States / cities: Palo Alto, California • Boston, Massachusetts • Minneapolis, Minnesota + 1 more

Conditions: Diabetic Retinopathy, NPDR - Non Proliferative Diabetic Retinopathy
Interventions: VX-01, Placebo; Drug
Lead sponsor: Vantage Biosciences Ltd; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 9
States / cities: Beverly Hills, California • Palo Alto, California • Santa Barbara, California + 6 more

Conditions: CKD Stage 3/4
Interventions: Vitamin D 2mg daily for 2 weeks oral paricalcitol, Placebo; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: QT Effects in Healthy Volunteers
Interventions: Moxidectin, Placebo; Drug · Other
Lead sponsor: Medicines Development for Global Health; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: West Bend, Wisconsin

Conditions: Fibrosis
Interventions: BMS-986263, Placebo, Diphenhydramine, Famotidine; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Cypress, California

Conditions: Anhedonia, Depression
Interventions: Carbidopa Levodopa, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 25 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Schizophrenia
Interventions: Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 34
States / cities: Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more

Conditions: Cognitive Function, Gaming Performance
Interventions: Placebo, Phosphatidylserine (100 mg), Phosphatidylserine (200 mg); Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: QVA149, Umeclidinium/vilanterol, Placebo (umeclidinium/vilanterol ), Placebo (QVA149); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 355 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 53
States / cities: Anaheim, California • Escondido, California • Riverside, California + 45 more

Conditions: Intimate Partner Violence
Interventions: ePREP, Placebo Control; Behavioral
Lead sponsor: Brigham Young University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tallahassee, Florida

Conditions: Rheumatoid Arthritis
Interventions: PF-04171327 10 mg, Prednisone Placebo, PF-04171327 25 mg, Prednisone 5 mg, Placebo for PF-04171327, Placebo; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 10
States / cities: Anniston, Alabama • Daytona Beach, Florida • Miami, Florida + 5 more

Conditions: Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
Interventions: Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 6
States / cities: Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more

Conditions: Carpal Tunnel Syndrome
Interventions: lidocaine patch 5%; Drug
Lead sponsor: Endo USA Inc., a Keenova Therapeutics Company; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Alzheimer's Disease
Interventions: VHB937, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 22
States / cities: Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more

Conditions: Depression, Depressive Disorder, Bipolar Disorder
Interventions: High dosage electroconvulsive therapy, Nortriptyline, Venlafaxine, Lithium, Low dosage electroconvulsive therapy; Procedure · Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years and older
Enrollment: 340 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 4
States / cities: St Louis, Missouri • New York, New York • Winston-Salem, North Carolina + 1 more

Search by objective public record fields.

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

CRT-Guanfacine for SPD

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT

A Long Term Study of Sibutramine and the Role of Obesity Management in Relation to Cardiovascular Disease in Overweight and Obese Patients

Effect of Vestibular Perceptual Learning on Vestibular Thresholds and Balance

Effects of Juice Plus+® Supplementation on Endothelial Function in Overweight Men

20101299: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms

Study Evaluating Vabicaserin in Subjects With Schizophrenia

The Effects of Mixhers HERTIME Supplements on Menstrual Symptoms

Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation

A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01

Identification of Markers for Determining the Efficacy of Vitamin D Receptor Activator Therapy in Stage 3/4 CKD Patients

Effect of a Single Oral Dose of Moxidectin on the Cardiac QT Interval of Healthy Volunteers

A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants

Dopaminergic Therapy for Anhedonia - 2

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

Dose-Response Effect of Phosphatidylserine on eSport Performance

Efficacy and Safety Study of Indacaterol Maleate/Glycopyrronium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients.

ePREP for Community Couples

A Study Of PF-04171327 In The Treatment Of The Signs And Symptoms Of Rheumatoid Arthritis

A Pharmacokinetic (PK) and Pharmacodynamic (PD) Dose-ranging Phase II Study of Ticagrelor in Paediatric Patients With Sickle Cell Disease

Safety and Efficacy of Lidoderm (Lidocaine Patch 5%) in Treating Moderate to Severe Pain Associated With Carpal Tunnel Syndrome

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Optimizing Electroconvulsive Therapy for Depression